Phylogeny  
• Member of the Tyrosine Kinase (TK) group, ErbB sub-family, clustering with EGFR/HER1, HER2 and HER3; cytoplasmic domain shares ≈79 % identity with EGFR (el‐gamal2021areviewof pages 1-3, el‐gamal2021areviewof pages 3-4).  
• Vertebrate orthologs include Mus musculus Erbb4, whose genetic ablation causes embryonic cardiac and neural defects (monsey2010her4andher2neu pages 1-2).  

Reaction Catalyzed  
• ATP + protein-L-tyrosine → ADP + protein-L-tyrosine-phosphate (qiu2008mechanismofactivation pages 6-7).  

Cofactor Requirements  
• Catalytic activity requires divalent cations; in vitro assays employ 10 mM Mn²⁺ for optimal phosphorylation (qiu2008mechanismofactivation pages 6-7).  

Substrate Specificity  
• The kinase phosphorylates generic tyrosine-containing peptides; no strict consensus motif was defined in biochemical assays (qiu2008mechanismofactivation pages 6-7).  

Structure  
• Domain organization: ectodomain with four β-hairpin subdomains and a cleavage-prone JM-a stalk, single transmembrane helix, intracellular juxtamembrane segment, bilobed kinase domain, C-terminal tail bearing multiple Tyr sites (el‐gamal2021areviewof pages 1-3, rio2000tumornecrosisfactorαconverting pages 1-2).  
• Crystal structures of the isolated kinase (PDB complexes with AMP-PNP and lapatinib) reveal canonical N- and C-lobes, an activation loop adopting active or inactive conformations, and a drug-occupied ATP pocket (qiu2008mechanismofactivation pages 6-7).  
• Active signaling requires asymmetric C-lobe/N-lobe dimers analogous to EGFR; dimerization is cooperative and concentration-dependent (monsey2010her4andher2neu pages 1-2).  
• Catalytic elements: Lys726 (β3) anchors ATP, Asp836 (HRD) is catalytic base, Phe837 stabilizes the regulatory spine, Thr771 and Met774 line the adenine pocket (sahu2017identificationandcharacterization pages 1-3).  
• JM-a–specific sequence confers susceptibility to TACE cleavage, a property absent in other ErbBs (rio2000tumornecrosisfactorαconverting pages 1-2).  

Regulation  
• Ligand binding by NRG1-4, BTC, EREG or HBEGF induces homo- or heterodimerization followed by trans-autophosphorylation (el‐gamal2021areviewof pages 3-4).  
• Principal autophosphorylation sites: Y984, Y1056, Y1188 (ojala2024recurrentcancerassociatederbb4 pages 34-35).  
• ERK-mediated feedback phosphorylation attenuates signaling (el‐gamal2021areviewof pages 24-25).  
• Proteolytic control: JM-a isoform is sequentially cleaved by TACE and γ-secretase, releasing a nuclear intracellular domain that chaperones STAT5A (rio2000tumornecrosisfactorαconverting pages 1-2, maatta2006proteolyticcleavageand pages 13-13).  
• Heterodimerization with HER2 markedly enhances kinase activity; co-expression with HER3 amplifies downstream Akt and ERK phosphorylation (monsey2010her4andher2neu pages 1-2, wandinger2016quantitativephosphoproteomicsanalysis pages 5-7).  
• Cancer-associated mutations such as K935I, Y285C and D595V increase dimerization, phosphorylation and intracellular-domain release (el‐gamal2021areviewof pages 6-7).  

Function  
• Widely expressed in fetal heart, nervous system, basal epidermis, skeletal muscle neuromuscular junctions, adult cardiomyocytes and mammary epithelium (el‐gamal2021areviewof pages 3-4).  
• Essential for cardiac trabeculation, neural crest migration, axon guidance, mammary differentiation and lactation (el‐gamal2021areviewof pages 1-3).  
• Activates PI3K/AKT and MAPK cascades; NRG1-stimulated homodimers induce BRCA1 and G2/M checkpoint, slowing proliferation in breast cancer cells (el‐gamal2021areviewof pages 7-9).  
• Co-expression with HER3 enhances Akt-Ser474 and MEK/ERK phosphorylation upon NRG1 stimulation (wandinger2016quantitativephosphoproteomicsanalysis pages 5-7).  
• Nuclear intracellular domain partners with STAT5A to regulate gene transcription (maatta2006proteolyticcleavageand pages 13-13).  

Inhibitors  
• Lapatinib – reversible; Ki = 347 nM (bose2009theerbbkinase pages 19-19).  
• Gefitinib – reversible; Ki = 1.1 µM (bose2009theerbbkinase pages 19-19).  
• Erlotinib – reversible; Ki = 1.5 µM (bose2009theerbbkinase pages 19-19).  
• Canertinib – irreversible; IC₅₀ = 14 nM (sahu2017identificationandcharacterization pages 9-11).  
• Ibrutinib – irreversible covalent inhibitor with HER4 activity (el‐gamal2021areviewof pages 15-17).  
• AC-480 (BMS-599626) – reversible; IC₅₀ = 190 nM (el‐gamal2021areviewof pages 15-17).  
• Pyrotinib – irreversible pan-HER inhibitor retaining HER4 affinity (el‐gamal2021areviewof pages 22-24).  
• Imidazo[2,1-b]thiazole derivatives (Compound I IC₅₀ = 15.24 nM; Compound II IC₅₀ = 17.70 nM) show >60-fold selectivity across 63 kinases (el‐gamal2021areviewof pages 15-17, el‐gamal2021areviewof pages 22-24).  

Other Comments  
• Context-dependent roles: phosphorylated HER4 associates with poor prognosis in glioblastoma, melanoma and gastric cancer (el‐gamal2021areviewof pages 7-9, el‐gamal2021areviewof pages 27-28).  
• Higher HER4 expression predicts favorable outcome in bladder and hormone-sensitive prostate cancers (el‐gamal2021areviewof pages 6-7, el‐gamal2021areviewof pages 27-28).  
• Recurrent activating mutations confer resistance to targeted therapies (ojala2024recurrentcancerassociatederbb4 pages 34-35).

References

1. (el‐gamal2021areviewof pages 1-3): M. El‐Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, H. Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin, and Hanan S. Anbar. A review of her4 (erbb4) kinase, its impact on cancer, and its inhibitors. Molecules, Dec 2021. URL: https://doi.org/10.3390/molecules26237376, doi:10.3390/molecules26237376. This article has 56 citations and is from a peer-reviewed journal.

2. (el‐gamal2021areviewof pages 24-25): M. El‐Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, H. Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin, and Hanan S. Anbar. A review of her4 (erbb4) kinase, its impact on cancer, and its inhibitors. Molecules, Dec 2021. URL: https://doi.org/10.3390/molecules26237376, doi:10.3390/molecules26237376. This article has 56 citations and is from a peer-reviewed journal.

3. (el‐gamal2021areviewof pages 3-4): M. El‐Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, H. Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin, and Hanan S. Anbar. A review of her4 (erbb4) kinase, its impact on cancer, and its inhibitors. Molecules, Dec 2021. URL: https://doi.org/10.3390/molecules26237376, doi:10.3390/molecules26237376. This article has 56 citations and is from a peer-reviewed journal.

4. (el‐gamal2021areviewof pages 7-9): M. El‐Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, H. Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin, and Hanan S. Anbar. A review of her4 (erbb4) kinase, its impact on cancer, and its inhibitors. Molecules, Dec 2021. URL: https://doi.org/10.3390/molecules26237376, doi:10.3390/molecules26237376. This article has 56 citations and is from a peer-reviewed journal.

5. (maatta2006proteolyticcleavageand pages 13-13): Jorma A. Määttä, Maria Sundvall, Teemu T. Junttila, Liisa Peri, V. Jukka O. Laine, Jorma Isola, Mikala Egeblad, and Klaus Elenius. Proteolytic cleavage and phosphorylation of a tumor-associated erbb4 isoform promote ligand-independent survival and cancer cell growth. Molecular Biology of the Cell, 17:67-79, Jan 2006. URL: https://doi.org/10.1091/mbc.e05-05-0402, doi:10.1091/mbc.e05-05-0402. This article has 176 citations and is from a domain leading peer-reviewed journal.

6. (monsey2010her4andher2neu pages 1-2): John Monsey, Wei Shen, Paul Schlesinger, and Ron Bose. Her4 and her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. Journal of Biological Chemistry, 285:7035-7044, Mar 2010. URL: https://doi.org/10.1074/jbc.m109.096032, doi:10.1074/jbc.m109.096032. This article has 77 citations and is from a domain leading peer-reviewed journal.

7. (ojala2024recurrentcancerassociatederbb4 pages 34-35): Veera K. Ojala, Sini Ahonen, Aura Tuohisto-Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, and Kari J. Kurppa. Recurrent cancer-associated erbb4 mutations are transforming and confer resistance to targeted therapies. BioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.19.626686, doi:10.1101/2024.12.19.626686. This article has 0 citations.

8. (qiu2008mechanismofactivation pages 6-7): Chen Qiu, Mary K. Tarrant, Sung Hee Choi, Aruna Sathyamurthy, Ron Bose, Sudeep Banjade, Ashutosh Pal, William G. Bornmann, Mark A. Lemmon, Philip A. Cole, and Daniel J. Leahy. Mechanism of activation and inhibition of the her4/erbb4 kinase. Structure, 16 3:460-7, Mar 2008. URL: https://doi.org/10.1016/j.str.2007.12.016, doi:10.1016/j.str.2007.12.016. This article has 224 citations and is from a domain leading peer-reviewed journal.

9. (rio2000tumornecrosisfactorαconverting pages 1-2): C. Río, J. Buxbaum, J. Peschon, and G. Corfas. Tumor necrosis factor-α-converting enzyme is required for cleavage of erbb4/her4*. The Journal of Biological Chemistry, 275:10379-10387, Apr 2000. URL: https://doi.org/10.1074/jbc.275.14.10379, doi:10.1074/jbc.275.14.10379. This article has 394 citations.

10. (sahu2017identificationandcharacterization pages 1-3): Ankita Sahu, P. K. Patra, M. Yadav, and M. Varma. Identification and characterization of erbb4 kinase inhibitors for effective breast cancer therapy. Journal of Receptors and Signal Transduction, 37:470-480, Jul 2017. URL: https://doi.org/10.1080/10799893.2017.1342129, doi:10.1080/10799893.2017.1342129. This article has 16 citations and is from a peer-reviewed journal.

11. (sahu2017identificationandcharacterization pages 9-11): Ankita Sahu, P. K. Patra, M. Yadav, and M. Varma. Identification and characterization of erbb4 kinase inhibitors for effective breast cancer therapy. Journal of Receptors and Signal Transduction, 37:470-480, Jul 2017. URL: https://doi.org/10.1080/10799893.2017.1342129, doi:10.1080/10799893.2017.1342129. This article has 16 citations and is from a peer-reviewed journal.

12. (wandinger2016quantitativephosphoproteomicsanalysis pages 5-7): S. Wandinger, I. Lahortiga, K. Jacobs, Martin Klammer, N. Jordan, Sarah Elschenbroich, M. Paradé, E. Jacoby, J. Linders, D. Brehmer, J. Cools, and H. Daub. Quantitative phosphoproteomics analysis of erbb3/erbb4 signaling. PLoS ONE, Jan 2016. URL: https://doi.org/10.1371/journal.pone.0146100, doi:10.1371/journal.pone.0146100. This article has 22 citations and is from a peer-reviewed journal.

13. (el‐gamal2021areviewof pages 27-28): M. El‐Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, H. Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin, and Hanan S. Anbar. A review of her4 (erbb4) kinase, its impact on cancer, and its inhibitors. Molecules, Dec 2021. URL: https://doi.org/10.3390/molecules26237376, doi:10.3390/molecules26237376. This article has 56 citations and is from a peer-reviewed journal.

14. (el‐gamal2021areviewof pages 6-7): M. El‐Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, H. Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin, and Hanan S. Anbar. A review of her4 (erbb4) kinase, its impact on cancer, and its inhibitors. Molecules, Dec 2021. URL: https://doi.org/10.3390/molecules26237376, doi:10.3390/molecules26237376. This article has 56 citations and is from a peer-reviewed journal.

15. (bose2009theerbbkinase pages 19-19): Ron Bose and Xuewu Zhang. The erbb kinase domain: structural perspectives into kinase activation and inhibition. Experimental cell research, 315 4:649-58, Feb 2009. URL: https://doi.org/10.1016/j.yexcr.2008.07.031, doi:10.1016/j.yexcr.2008.07.031. This article has 99 citations and is from a peer-reviewed journal.

16. (el‐gamal2021areviewof pages 15-17): M. El‐Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, H. Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin, and Hanan S. Anbar. A review of her4 (erbb4) kinase, its impact on cancer, and its inhibitors. Molecules, Dec 2021. URL: https://doi.org/10.3390/molecules26237376, doi:10.3390/molecules26237376. This article has 56 citations and is from a peer-reviewed journal.

17. (el‐gamal2021areviewof pages 22-24): M. El‐Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, H. Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin, and Hanan S. Anbar. A review of her4 (erbb4) kinase, its impact on cancer, and its inhibitors. Molecules, Dec 2021. URL: https://doi.org/10.3390/molecules26237376, doi:10.3390/molecules26237376. This article has 56 citations and is from a peer-reviewed journal.
